Overview

Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.
Phase:
Phase 4
Details
Lead Sponsor:
Innovaderm Research Inc.
Treatments:
Abrocitinib